MaaT013: Positive Topline Phase 3 results

See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

April 14, 2025

April 14, 2025: Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)

April 8, 2025

April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

April 7, 2025

April 7, 2025: MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co

Like what you see? See more posts

Our upcoming events

Event
April 18, 2025

AACR Annual Meeting 2025

• April 25-30, 2025 – AACR Annual Meeting, Chicago, IL
MaaT Pharma
Event
April 18, 2025

Swiss Biotech Day 2025

• May 5-6, 2025 – Swiss Biotech Day 2025
MaaT Pharma
Event
April 18, 2025

Midcaps Forum – Gilbert Dupont

• May 13, 2025 – Small & Midcaps Forum, Gilbert Dupont
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers